Globus Medical will announce Q4 and full-year 2024 financial results on February 20, 2025, followed by a teleconference.
Quiver AI Summary
Globus Medical, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2024, after the market closes on February 20, 2025. Following this announcement, the company will host a teleconference at 4:30 p.m. Eastern Time to discuss its performance, which can be accessed via a live webcast or by telephone after prior registration. Globus Medical, based in Audubon, Pennsylvania, focuses on innovative musculoskeletal solutions and provides education and clinical support in various medical fields. The press release also includes a safety disclaimer regarding forward-looking statements, emphasizing the inherent risks and uncertainties that could affect the company's future outcomes. For more details, individuals are encouraged to visit the company's website or engage with their investor relations contacts.
Potential Positives
- Globus Medical, Inc. will release its financial results for Q4 and the full year ended December 31, 2024, providing investors with important insights into the company's performance.
- The release will be followed by a teleconference, allowing for direct engagement with the investment community to discuss the results and company strategies.
- Audio archives of the teleconference will be made available, ensuring that information is accessible to shareholders and interested parties who cannot attend live.
- Globus Medical is positioned as a leader in the musculoskeletal solutions sector, emphasizing its commitment to innovation and addressing unmet clinical needs in healthcare.
Potential Negatives
- The press release contains multiple forward-looking statements that highlight various risks and uncertainties, particularly regarding the integration of the NuVasive business, which could indicate potential challenges ahead.
- The mention of the company's ability to sustain profitability and manage growth raises concerns about their current financial health and operational effectiveness.
- There is an explicit caution against placing undue reliance on forward-looking statements, suggesting that actual results may vary significantly from current expectations, which could undermine investor confidence.
FAQ
When will Globus Medical announce its fourth quarter financial results?
Globus Medical will announce its fourth quarter and full-year financial results on February 20, 2025, after market close.
How can I listen to the Globus Medical earnings call?
You can listen to the earnings call live via webcast on the Investors page of Globus Medical’s website.
What time is the Globus Medical teleconference scheduled?
The teleconference is scheduled for 4:30 p.m. Eastern Time on February 20, 2025.
Will there be an audio archive of the earnings call?
Yes, an audio archive of the call will be available on the Investors page of the Globus Medical website.
Where can I find more information about Globus Medical?
Additional information about Globus Medical can be accessed at their official website, www.globusmedical.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GMED Insider Trading Activity
$GMED insiders have traded $GMED stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:
- DANIEL T SCAVILLA (President, CEO) has made 0 purchases and 2 sales selling 190,000 shares for an estimated $15,851,200.
- DAVID D DAVIDAR has made 0 purchases and 7 sales selling 115,000 shares for an estimated $8,913,362.
- KEITH W PFEIL (COO, CFO) has made 0 purchases and 2 sales selling 14,167 shares for an estimated $1,250,770.
- DAN LEMAITRE has made 0 purchases and 2 sales selling 14,375 shares for an estimated $1,221,893.
- KELLY HULLER (SVP, GC, Corporate Secretary) has made 0 purchases and 4 sales selling 15,000 shares for an estimated $1,185,200.
- ANN D RHOADS sold 15,000 shares for an estimated $1,055,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GMED Hedge Fund Activity
We have seen 189 institutional investors add shares of $GMED stock to their portfolio, and 231 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 900,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $64,386,000
- CITADEL ADVISORS LLC added 806,296 shares (+103.3%) to their portfolio in Q3 2024, for an estimated $57,682,415
- MILLENNIUM MANAGEMENT LLC removed 714,568 shares (-52.4%) from their portfolio in Q3 2024, for an estimated $51,120,194
- CHAMPLAIN INVESTMENT PARTNERS, LLC removed 671,821 shares (-27.2%) from their portfolio in Q3 2024, for an estimated $48,062,074
- WELLINGTON MANAGEMENT GROUP LLP removed 631,239 shares (-19.7%) from their portfolio in Q3 2024, for an estimated $45,158,838
- ARROWMARK COLORADO HOLDINGS LLC added 614,295 shares (+inf%) to their portfolio in Q3 2024, for an estimated $43,946,664
- LORD, ABBETT & CO. LLC added 530,451 shares (+inf%) to their portfolio in Q3 2024, for an estimated $37,948,464
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .
Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts .
To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
The audio archive will be available after the call on the Investors page of the Globus Medical website.
About Globus Medical, Inc.
Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive business and our ability to successfully integrate and to achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changes and applicable laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Contacts:
Investors:
Brian Kearns
Senior Vice President, Corporate Development and Investor Relations
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com
Media:
Moran Chavez
Senior Director, Corporate Affairs
Phone: (619) 318-7681
Email: [email protected]